Navigation Links
Yale scientists show that a microRNA can reduce lung cancer growth
Date:3/20/2008

New Haven, Conn. A small RNA molecule, known as let-7 microRNA (miRNA), substantially reduced cancer growth in multiple mouse models of lung cancer, according to work by researchers at Yale University and Asuragen, Inc., published in the journal Cell Cycle.

Cancer afflicts 1.5 million people a year in the United States alone, and lung cancer is the most common and deadly form of cancer worldwide. This study indicates a direct role for a miRNA in cancer progression and introduces a new paradigm of using miRNAs as effective therapeutic agents to treat human cancer.

We believe this is the first report of a miRNA being used to a beneficial effect on any cancer, let alone lung cancers, the deadliest of all cancers worldwide, said senior author Frank Slack, associate professor of molecular, cellular and developmental biology at Yale.

Slacks research group initially discovered the let-7 miRNA in C. elegans, a tiny worm used as a model system for studying how organisms develop, grow and age. They went on to show that in humans, let-7 negatively regulates a well-known determinant of human lung cancers, the RAS oncogene.

In collaboration with scientists at Asuragen, the Slack lab has studied the tumor suppressor activity of this small RNA. Their work revealed that let-7 is commonly present at substantially reduced levels in lung tumors and that reduced levels of let-7 likely contribute to the development of the tumors. These discoveries focused public attention and research efforts to understand the potential use of naturally occurring microRNAs like let-7 to combat cancer.

This new work demonstrates that let-7 inhibits the growth of lung cancer cells in culture and in lung tumors in mice. They also showed that let-7 can be applied as an intranasal drug to reduce tumor formation in a RAS mouse model lung cancer.

We believe that our studies provide the first direct evidence in mammals, that let-7 functions as a tumor suppressor gene, said Slack. Because multiple cell lines and mouse models of lung cancer were used, it appears that therapeutic application of let-7 may provide benefits to a broad group of lung cancer patients.

This has been a very productive industry-academic collaboration between Yale and Asuragen scientists commented Matt Winkler CEO of Asuragen. This work provides further evidence of the importance of miRNAs in the development of cancer and provides additional support for miRNA replacement therapy as an important component of effective cancer treatment regimens of the future.


'/>"/>

Contact: Janet Rettig Emanuel
janet.emanuel@yale.edu
203-432-2157
Yale University
Source:Eurekalert  

Related biology news :

1. Texas A&M scientists say early Americans arrived earlier
2. Scientists find color vision system independent of motion detection
3. Crop scientists discover gene that controls fruit shape
4. Scientists discover how TB develops invincibility against only available treatment
5. Scientists show that streams are critical to preservation of oceanic coastal zones
6. Scientists to discover why flamingos are in the pink of health -- in the poo!
7. Scientists believe photograph depicts wolverine in California
8. Scientists successfully treat new mouse model of inflammatory bowel disease
9. Genes hold the key to how happy we are, scientists say
10. Scientists uncover a novel mechanism that regulates carbon dioxide fixation in plants
11. Bright lights: Mystery of glowing antibody solved by Scripps research scientists
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Yale scientists show that a microRNA can reduce lung cancer growth
(Date:4/11/2017)... , April 11, 2017 Crossmatch®, a ... authentication solutions, today announced that it has been ... Research Projects Activity (IARPA) to develop next-generation Presentation ... "Innovation has been a driving force ... program will allow us to innovate and develop ...
(Date:4/6/2017)... 2017 Forecasts by Product Type ... by End-Use (Transportation & Logistics, Government & Public Sector, ... Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation ... Are you looking for a definitive report on the ... ...
(Date:4/4/2017)... April 4, 2017   EyeLock LLC , a ... the United States Patent and Trademark Office (USPTO) has ... the linking of an iris image with a face ... represents the company,s 45 th issued patent. ... very timely given the multi-modal biometric capabilities that have ...
Breaking Biology News(10 mins):
(Date:8/16/2017)... OH (PRWEB) , ... August 16, 2017 , ... ... a beneficial microbe delivery system, announced it has secured $2M in funding from ... Queen City Angels, Carmen Innovations, and SVG Thrive Fund. With this investment, 3Bar ...
(Date:8/15/2017)... ... ... Kapstone Medical is proud to announce that it has reached a ... develop and safeguard their latest innovations. The company has grown from a boutique ... in the United States and around the world. , Company Founder and President, ...
(Date:8/15/2017)... ... August 15, 2017 , ... The Conference Forum ... Immuno-Oncology 360° (IO360°) programming through a series of upcoming panels and events. The partnership ... 2018, at The Roosevelt Hotel in New York City. , “With our experience in ...
(Date:8/14/2017)... ... 14, 2017 , ... The Conference Forum has confirmed the one-day ... on September 6, 2017 at the Marriott Copley Place in Boston, MA. , Returning ... and Regulatory Strategy, Pfizer Innovative Research Lab, Pfizer, who leads 19 industry speakers in ...
Breaking Biology Technology: